The first meeting of international specialists in the field of von Willebrand disease (VWD) was held in the Åland islands in 1998 where Erik von Willebrand had first observed a bleeding disorder in some members of a family from Föglö and a summary of the meeting was published in 1999. The second meeting was held in 2010 and a report of the meeting was published in 2012. Topics covered included progress in understanding of VWD over the last 50 years; multimers; classification of VWD; pharmacokinetics and laboratory assays; genetics; treating the paediatric patient; prophylaxis; geriatrics; gene therapy and treatment guidelines. This third meeting held over 3 days covered the structure and function of von Willebrand factor (VWF); type 1 VWD, the most common form of the disease; a lifespan of pharmacokinetics in VWD; detecting inhibitors in VWD patients; and special challenges in understanding and treating the female VWD patient.
Third Åland islands conference on von Willebrand disease, 26-28 September 2012 : meeting report / E. Berntorp, B. Fuchs, M. Makris, R. Montgomery, V. Flood, J.S. O'Donnell, A.B. Federici, D. Lillicrap, P. James, U. Budde, M. Morfini, P. Petrini, S. Austin, C. Kannicht, V. Jiménez-Yuste, C. Lee. - In: HAEMOPHILIA. - ISSN 1351-8216. - 19:supplement 3(2013 Mar), pp. 1-18. ((Intervento presentato al 3. convegno Conference on von Willebrand disease tenutosi a Mariehamn (Aland, Finland) nel 2012 [10.1111/hae.12078].
Third Åland islands conference on von Willebrand disease, 26-28 September 2012 : meeting report
A.B. Federici;
2013
Abstract
The first meeting of international specialists in the field of von Willebrand disease (VWD) was held in the Åland islands in 1998 where Erik von Willebrand had first observed a bleeding disorder in some members of a family from Föglö and a summary of the meeting was published in 1999. The second meeting was held in 2010 and a report of the meeting was published in 2012. Topics covered included progress in understanding of VWD over the last 50 years; multimers; classification of VWD; pharmacokinetics and laboratory assays; genetics; treating the paediatric patient; prophylaxis; geriatrics; gene therapy and treatment guidelines. This third meeting held over 3 days covered the structure and function of von Willebrand factor (VWF); type 1 VWD, the most common form of the disease; a lifespan of pharmacokinetics in VWD; detecting inhibitors in VWD patients; and special challenges in understanding and treating the female VWD patient.File | Dimensione | Formato | |
---|---|---|---|
Haemophilia 2013.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
654.38 kB
Formato
Adobe PDF
|
654.38 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.